SEC Form 4 · accession 0001209191-16-110440
Sierra Oncology, Inc. · SRRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wendy Chapman
Officer — SVP Clinical Operations
Period of report
Mar 22, 2016
Accepted (ET)
Mar 24, 2016 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001290149
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 22, 2016 | M | 3,000 | $0.969 | A | 3,000 | D | |
| Common StockF2 | Mar 22, 2016 | S | 3,000 | $7.0078 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $0.969 | Mar 22, 2016 | M | 3,000 | D | — | Sep 22, 2024 | Common Stock | 3,000 | 76,248 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The option vests as to 25% of the total shares on September 22, 2015, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on September 22, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. The option is immediately exercisable.